Journal
ONCOTARGETS AND THERAPY
Volume 11, Issue -, Pages 5631-5646Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S164984
Keywords
long noncoding RNAs; DHRS4-AS1; clear cell renal cell carcinoma; prognosis
Categories
Funding
- National Natural Science Foundation of China [81171996, 81272289]
- Wujieping Medical Foundation [320.6750.13252]
- First Affiliated Hospital of Harbin Medical University Science Foundation [2015B011]
Ask authors/readers for more resources
Background: Long noncoding RNAs (lncRNAs) have been identified as important factors in cancer biology and are deregulated in many cancers. The present study aimed to determine the expression and roles of lncRNA DHRS4-AS1 in the progression of clear cell renal cell carcinoma (ccRCC). Methods and results: Using high-throughput RNA-sequencing data of ccRCC tumors from the Cancer Genome Atlas project, we identified lncRNA DHRS4-AS1 as significantly associated with ccRCC patients' overall survival. We confirmed the downregulation of DHRS4-AS1 in ccRCC by assessing its expression levels in a cohort of 52 tumor and paired non-tumor samples. In addition, we found that low DHRS4-AS1 expression was significantly associated with a high tumor node metastasis stage, lymph node metastasis, advanced pathological grade and poor prognosis. Furthermore, DIRS4-AS1 overexpression inhibited the progression of cell cycles of ccRCC in vitro. These data indicate that DHRS4-AS1 functions by preventing the proliferation and invasion, inhibiting the cell cycle progression and promoting the apoptosis of ccRCC cells. Conclusion: Taken together, our findings identify the role of DHRS4-AS1 as a tumor inhibitor in cc RCC for the first time, demonstrating that DHRS4-AS1 is a potential prognostic biomarker that could potentially be applied in ccRCC therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available